drugset / Trial / NCT05217498

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

NCT05217498

Phase 1/2 Not yet recruiting 40 enrolled Randy Trumbower, PT, PhD
RandomizedCrossoverTriple-blindTreatment

Summary

Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking ability occur when LOT is administered prior to skill-based walking practice (WALK). However, the enduring benefits of LOT on walking recovery may be undermined by the accumulation of LOT-induced increase in extracellular adenosine. The goal of the study is to understand the extent to which istradefylline (adenosine 2a receptor antagonist) may limit the competing mechanisms of adenosine on LOT-induced walking recovery following SCI.

Timeline

Start
2027-09-01
Primary completion
2027-12-30
Completion
2028-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 20 mg Oral

Indications